JP2013532489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532489A5 JP2013532489A5 JP2013523288A JP2013523288A JP2013532489A5 JP 2013532489 A5 JP2013532489 A5 JP 2013532489A5 JP 2013523288 A JP2013523288 A JP 2013523288A JP 2013523288 A JP2013523288 A JP 2013523288A JP 2013532489 A5 JP2013532489 A5 JP 2013532489A5
- Authority
- JP
- Japan
- Prior art keywords
- genes
- cancer
- subset
- gene
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 252
- 206010028980 Neoplasm Diseases 0.000 claims description 195
- 238000000034 method Methods 0.000 claims description 131
- 201000011510 cancer Diseases 0.000 claims description 112
- 230000014509 gene expression Effects 0.000 claims description 112
- 238000011282 treatment Methods 0.000 claims description 103
- 210000004027 cell Anatomy 0.000 claims description 93
- 201000009030 Carcinoma Diseases 0.000 claims description 50
- 239000003795 chemical substances by application Substances 0.000 claims description 45
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 44
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 41
- 229930012538 Paclitaxel Natural products 0.000 claims description 40
- 229960001592 paclitaxel Drugs 0.000 claims description 40
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 claims description 37
- 239000004189 Salinomycin Substances 0.000 claims description 37
- 229960001548 salinomycin Drugs 0.000 claims description 37
- 235000019378 salinomycin Nutrition 0.000 claims description 37
- 238000011272 standard treatment Methods 0.000 claims description 36
- 238000000528 statistical test Methods 0.000 claims description 34
- 230000002018 overexpression Effects 0.000 claims description 31
- 210000000130 stem cell Anatomy 0.000 claims description 27
- 238000011275 oncology therapy Methods 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 22
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 231100000331 toxic Toxicity 0.000 claims description 20
- 230000002588 toxic effect Effects 0.000 claims description 20
- 238000002271 resection Methods 0.000 claims description 17
- 101150084750 1 gene Proteins 0.000 claims description 16
- 239000000090 biomarker Substances 0.000 claims description 16
- 238000011301 standard therapy Methods 0.000 claims description 14
- 101150028074 2 gene Proteins 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 230000007774 longterm Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 238000011277 treatment modality Methods 0.000 claims description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
- 238000010199 gene set enrichment analysis Methods 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000000692 Student's t-test Methods 0.000 description 12
- 238000012353 t test Methods 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000002626 targeted therapy Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000009274 differential gene expression Effects 0.000 description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000011319 anticancer therapy Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000003208 gene overexpression Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36992810P | 2010-08-02 | 2010-08-02 | |
| US61/369,928 | 2010-08-02 | ||
| PCT/US2011/046325 WO2012018857A2 (en) | 2010-08-02 | 2011-08-02 | Prediction of and monitoring cancer therapy response based on gene expression profiling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013532489A JP2013532489A (ja) | 2013-08-19 |
| JP2013532489A5 true JP2013532489A5 (enExample) | 2014-09-04 |
Family
ID=45560038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523288A Pending JP2013532489A (ja) | 2010-08-02 | 2011-08-02 | 遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130260376A1 (enExample) |
| EP (1) | EP2601315A4 (enExample) |
| JP (1) | JP2013532489A (enExample) |
| CA (1) | CA2806726A1 (enExample) |
| WO (1) | WO2012018857A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140005260A1 (en) * | 2012-06-28 | 2014-01-02 | Tri-Service General Hospital | Method for inhibiting cancer metastasis by amiodarone |
| KR101717177B1 (ko) * | 2013-10-28 | 2017-03-16 | 주식회사 디앤피바이오텍 | 항암제 치료 반응성 및 생존 예후 예측용 마커 |
| WO2015175305A1 (en) | 2014-05-12 | 2015-11-19 | Janssen Pharmaceutica Nv | Biological markers for identifying patients for treatment with abiraterone acetate |
| JP6761798B2 (ja) * | 2014-09-03 | 2020-09-30 | ウェルマーカー バイオ カンパニー リミテッド | タンパク質キナーゼ阻害剤に対する感受性予測用組成物、キット、及び方法 |
| CN105886628B (zh) * | 2016-04-29 | 2019-03-26 | 肖刻 | Sprr1a基因在制备骨关节炎诊断产品中的应用 |
| US20200071773A1 (en) * | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| CN112867495B (zh) * | 2018-10-19 | 2024-08-20 | 韩国生命工学研究院 | 包含syt11抑制剂作为活性成分的胃癌治疗组合物 |
| WO2020115261A1 (en) * | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| US7892740B2 (en) * | 2006-01-19 | 2011-02-22 | The University Of Chicago | Prognosis and therapy predictive markers and methods of use |
| EP2036988A1 (en) * | 2007-09-12 | 2009-03-18 | Siemens Healthcare Diagnostics GmbH | A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent |
| WO2009074968A2 (en) * | 2007-12-12 | 2009-06-18 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for predicting the efficacy of cancer therapy |
| CA2723648A1 (en) * | 2008-04-10 | 2009-10-15 | Piyush Gupta | Methods for identification and use of agents targeting cancer stem cells |
| RU2011101378A (ru) * | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии |
| WO2010076322A1 (en) * | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
| US20140030255A1 (en) * | 2010-11-03 | 2014-01-30 | Merck Sharp & Dohme Corp. | Methods of predicting cancer cell response to therapeutic agents |
| EP2702173A1 (en) * | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
-
2011
- 2011-08-02 CA CA2806726A patent/CA2806726A1/en active Pending
- 2011-08-02 EP EP11815224.8A patent/EP2601315A4/en not_active Withdrawn
- 2011-08-02 US US13/813,150 patent/US20130260376A1/en not_active Abandoned
- 2011-08-02 JP JP2013523288A patent/JP2013532489A/ja active Pending
- 2011-08-02 WO PCT/US2011/046325 patent/WO2012018857A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Construction of an immune-related six-lncRNA signature to predict the outcomes, immune cell infiltration, and immunotherapy response in patients with hepatocellular carcinoma | |
| JP2013532489A5 (enExample) | ||
| JP2013532489A (ja) | 遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング | |
| WO2008151072A1 (en) | Multigene prognostic assay for lung cancer | |
| JP2015530072A (ja) | ゲムシタビン療法による乳癌の治療方法 | |
| ES2882875T3 (es) | Método de pronóstico y predicción de la recurrencia del cáncer de mama, marcadores empleados en el mismo y kit del mismo | |
| AU2012279173A1 (en) | Multigene prognostic assay for lung cancer | |
| EP2649198A1 (en) | Marker for carcinoma | |
| US20130143753A1 (en) | Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom | |
| Pankotai-Bodó et al. | Routine molecular applications and recent advances in breast cancer diagnostics | |
| WO2007034221A2 (en) | Non small cell lung cancer therapy prognosis and target | |
| CN106662543A (zh) | 肺癌患者中的非侵入性基因突变检测 | |
| Zhu et al. | Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma | |
| Li et al. | AGR2 diagnostic value in nasopharyngeal carcinoma prognosis | |
| Cai et al. | High-expression of ZBP-89 correlates with distal metastasis and poor prognosis of patients in clear cell renal cell carcinoma | |
| Liu et al. | Elevated expression of Thoc1 is associated with aggressive phenotype and poor prognosis in colorectal cancer | |
| Zaki-Dizaji et al. | Tumor-educated platelet, a potential liquid biopsy biosource in pancreatic cancer: A review | |
| Shao et al. | The role of gene expression profiling in early-stage non-small cell lung cancer | |
| Huang et al. | A comprehensively prognostic and immunological analysis of chloride intracellular channel protein 5 (CLIC5) in pan-cancer and identification in ovarian cancer | |
| US20150011411A1 (en) | Biomarkers of cancer | |
| US20120129711A1 (en) | Biomarkers for the prognosis and high-grade glioma clinical outcome | |
| Chang et al. | Optimization of a multigene biochip for detection of relapsed and early relapsed colorectal cancer | |
| JP2017529074A (ja) | 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 | |
| Gao et al. | A tumor microenvironment-related mRNA–ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma | |
| WO2015161885A1 (en) | Hepatocyte growth factor as marker of prognosis in small cell lung cancer (sclc) |